secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027721
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M
--------------------------------------------------------------------------------

- Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).
- GAAP net income $27.6M ($0.10 EPS basic) vs loss of $11.9M in 2023; non-GAAP net income $67.7M ($0.25 EPS).
- Reduced debt principal by $236M, remaining $36M convertible notes; year-end cash $203M.
- Afrezza INHALE-1 pediatric trial met primary endpoint; FDA meeting planned 1H 2025 for potential sNDA.
- MNKD-101 Phase 3 interim enrollment target expected by YE 2025; MNKD-201 Phase 1 completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017025027721/0000950170-25-027721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017025027721/mnkd-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer